openPR Logo
Press release

Generic Drugs Market - Global Industry Insights, Trends, Outlook, and Analysis, 2017-2025

01-30-2018 01:31 PM CET | Health & Medicine

Press release from: CMI - Pharmaceutical Research

Generic Drugs Market - Global Industry Insights, Trends,

Generic drugs refers to medication that have the same active ingredient as that of a branded drugs. These drugs also yield the same therapeutic effect and are prescribed in the same dosing, with the same quality, and same the way of consumption and usage. However, the inactive ingredients of generic drugs can differ as compared to their branded counter parts. These drugs are mainly marketed after a patent expiry of a branded drug and are significantly lower in costs as compared to the patented branded drugs. Generic drugs are of equivalent quality as compared to the branded drugs and are manufactured under the same safety and manufacturing procedures. Various manufacturers submit an abbreviated new drug application (ANDA) to the FDA after the completion of period of patent exclusivity.

Request Table of Content Of This Report: https://www.coherentmarketinsights.com/ongoing-insight/toc/1132

Patent expiry of branded drugs is a factor expected to boost growth of the global generic drugs market

Manufacturers of generic drugs are focusing on development and introduction of various innovative medication and formulation such as biosimilars. According to IMS Health data, generic drugs accounted for over 80% of the prescriptions dispensed in the U.S. in 2013. The number of patents expiring in the near future serves to be a major driver for growth of generic drugs market. For instance, Cetuximab (Erbitux) is an epidermal growth factor receptor inhibitor that is indicated in the treatment of metastatic colorectal cancer and head and neck cancer. It is manufactured under the patent by Bristol-Myers Squibb and Eli Lily Company in Europe. The drug’s patent expires in 2018 and thus, is expected to provide opportunity for a large number of market players to manufacture its generic version. Furthermore, supportive initiative by FDA to promote development of biosimilars is encouraging manufacturers to focus towards its development. For instance, the Biologics Price Competition and Innovation Act in the U.S. gr ants 12 months patent exclusivity with higher profit margins to the first manufacturer than the conventional generic manufacturers bringing the drugs in market later. Various other factors contributing to growth of generic drugs market include rampant growth in incidence of chronic diseases. However, shortage of active pharmaceutical ingredients leading to unavailability of generics in the market and increasing FDA pressure on manufacturers regarding manufacturing quality of these drugs are hindering the market growth.

Market Taxonomy

The global generic drugs market is segmented on the basis of drug type, therapeutic application, route of administration, and region.

On the basis of Drug Type, the global generic drugs market is segmented into:

Monoclonal Antibodies,Cytokines,Vaccines,Insulin,Peptide Hormones,Immunoglobulin,Peptide Antibiotics,Blood Factors,Others,.

On the basis of Therapeutic Application, the global generic drugs market is segmented into:

Oncology,Cardiovascular Diseases,Neurology,Infectious Diseases,Musculoskeletal Diseases,Others,.

Based on Route of Administration, the global generic drugs market is segmented into:

Oral,Topical,Injectable,Intra-venous,Others,.

Asia Pacific to gain significant traction in the global generic drugs market owing to increasing number of local players

On the basis of region, the global generic drugs market is segmented into North America, Latin America, Europe, Asia Pacific, Middle East, and Africa. North America held a dominant position in the global generic drugs market in 2016. This is attributed to favorable regulatory policies that are revised and amended to encourage generic drugs business in the region. For instance, Generic Drug User Fee Amendment (GDFUA) was reauthorized in 2017 after its initiation in 2012 by FDA for increasing consumer access to high quality, safe, and affordable drugs. On the other hand, Asia Pacific is expected to show a significant traction in the market over the forecast period. This is attributed to lower manufacturing costs and high skilled workforce in the Asian countries. According to India Brand Equity Foundation, India has the second largest number of U.S. FDA manufacturing plants outside the U.S. that are involved in generic drugs manufacturing. Additionally, the cost of manufacturing is 33% lower in India than that in the U.S., increasing accessibility to generics in these countries.

New drug launches and market approvals from the U.S. FDA to generic manufacturers are bolstering growth of the generic drugs market. For instance, in December 2017, Zydus Phamaceuticals — a subsidiary of Cadila Healthcare — received U.S. FDA approval to market Pramipexole Dihydrochloride extended-release tablets for the treatment of Parkinson ’s disease in the U.S. market. Key players operating in the global generic drugs market are Teva Pharmaceutical Industries, Mylan N.V., Novartis International AG, Pfizer, Inc., Allergan Plc, Sun Pharmaceuticals, Fresenius Kabi, Sanofi, Endo International, Lupin Ltd., Abbott Healthcare, AstraZeneca Plc, and Novo Nordisk.

Browse The Complete Report @ https://www.coherentmarketinsights.com/ongoing-insight/generic-drugs-market-1132

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:

Mr. Shah
Coherent Market Insights
1001 4th Ave,
#3200
Seattle, WA 98154
Tel: +1-206-701-6702
Visit our news Website: http://www.coherentnews.com

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Generic Drugs Market - Global Industry Insights, Trends, Outlook, and Analysis, 2017-2025 here

News-ID: 922824 • Views:

More Releases from CMI - Pharmaceutical Research

Breast Lesion Localization Methods Market - Global Industry Insights, Trends, Outlook, and Opportunity Analysis, 2018-2026
Breast Lesion Localization Methods Market - Global Industry Insights, Trends, Ou …
Breast cancer is a condition characterized by an uncontrolled multiplication of breast cells that form a lump, which may be malignant or non-malignant in nature. Such cells usually form tumors that can often be observed on an x-ray or felt as a lump. Breast cancer occurs most commonly among women aged 40 years and above along with a small percentage of men affected by the same. A novel technique of
Southern Blotting Market - BioRad Laboratories, Agilent Technologies, ThermoFisher Scientific, Perkin Elmer Inc.
Southern Blotting Market - BioRad Laboratories, Agilent Technologies, ThermoFish …
Molecular biology has gained significant momentum over the last decade with increasing R&D spending on development of therapeutic drugs. It has wide role across various healthcare industry verticals- most prominent in clinical trials and diagnostic purposes. Among such technology, southern blotting has gained significant traction offering substantial market opportunities for the players across value chain. The technique was first introduced in 1970’s to detect presence of DNA fragment in samples.
Cancer Vaccine Market - Global Industry Insights, Size, Trends, Outlook, and Analysis, 2017-2025
Cancer Vaccine Market - Global Industry Insights, Size, Trends, Outlook, and Ana …
Cancer is the second leading cause of morbidity and mortality worldwide. Major cause of cancer is gene mutation and rarely due to inherited genes. On the basis of the type of cell it initiates to form cancerous with, it is divided into carcinoma, lymphomas, leukaemias, brain tumors, and sarcomas. According to World Health Organization (WHO), 2017, nearly 1 in 6 deaths is due to cancer globally and around 70% of
Parkinson’s Disease Therapeutic Market — Global Industry Insights, Trends, Outlook, and Opportunity Analysis, 2017–2025
Parkinson’s Disease Therapeutic Market — Global Industry Insights, Trends, O …
Parkinson’s disease (PD) is a chronic disorder characterized by the malfunctioning and death of vital nerve cells in the brain, and can be characterized by tremor, dementia, and depression. Parkinson’s disease progression leads to uncontrolled body movement of the patient. There is no cure presently for parkinson’s disease only treatments options such as medication and surgery to manage the symptoms are available. Parkinson’s disease mainly affects people over 50 and

All 5 Releases


More Releases for FDA

DreaMed receives 5th FDA Clearance
TEL AVIV, Israel: DreaMed Diabetes LTD. ("DreaMed" or the "Company"), developer of the endo.digital Clinical Decision Support System announced today that it has received its 5th U.S Food and Drug Administration (FDA) clearance that expands the scope of AI enhanced treatment recommendations to patients on fixed meal insulin regimens. endo.digital is the first decision support system that has been cleared to assist healthcare providers in the management of diabetes
FDA Compliant Blood Storage and Preservation
Accsense Monitoring System Automates Data Archive and Alarming CAS DataLoggers provided the temperature alarming and monitoring system to a hospital blood bank looking to replace their old paper chart recorders as they became unreliable and spare parts were harder to find. For proper blood storage and preservation, the lab’s medical units needed to maintain storage temperatures between 2°C to 6°C (36°F to 43°F), given the perishability of blood components. The facility
FDA grants orphan drug status to Vicore
US Food and Drug Administration has awarded Vicore Pharmaceuticals with orphan Drug designation for the treatment of Idiopathic Pulmonary Fibrosis (IPF). FDA’s Orphan Drug Designation program provides certain incentives for companies developing therapeutics to treat rare diseases or conditions, defined as those affecting less than 200,000 individuals in the U.S. A drug candidate and its sponsor must meet several key criteria in order to qualify for, and obtain, orphan drug
New FDA Design Control Training Courses
Salt Lake City, Utah - February 23 2017 - Procenius Consulting is a medical device consulting firm specializing solely in medical device design controls regulation (21 CFR 820.30). Announcing New Design Control Training Courses Procenius Consulting has just launched two new training courses covering basic and advanced topics of medical device design control regulation. These courses focus on compliance, practical implementation and industry best practices techniques for developing or improving a
fda online training
GRC Training Solutions provides end-to-end FDA compliance solutions for those companies who want to maximize security, minimize operational costs, improve staff productivity and stay on top of all their compliance documentation. GRC Training Solutions boasts a team of experts and specialists who have a proven track record in working with the biotechnology, medical device, diagnostic and pharmaceutical fields. Our team will work with you closely and develop solutions that meet
11-09-2016 | Science & Education
GRCTS
FDA online training
Description: Device firms, establishments or facilities that are involved in the production and distribution of medical devices intended for use in the U.S are required to register annually. Most establishments that are required to register with the FDA are also required to list the devices that are made there and the activities that are performed on those devices. Initially, FDA issued a 28-page Proposed Rule that would amend its regulations regarding